Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Toremifene citrate
Drug ID BADD_D02250
Description A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.
Indications and Usage For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
Marketing Status approved; investigational
ATC Code L02BA02
DrugBank ID DB00539
KEGG ID D00967
MeSH ID D017312
PubChem ID 3005572
TTD Drug ID D04VFJ
NDC Product Code 64980-404; 17337-0305; 90027-020; 73377-183; 72205-050; 52483-0060; 73309-291; 42747-327; 69539-152; 54893-0079
UNII 2498Y783QT
Synonyms Toremifene | Toremifene, (E)-Isomer | Toremifene Citrate | Citrate, Toremifene | Toremifene Citrate (1:1) | Fareston | FC-1157a | FC 1157a | FC1157a
Chemical Information
Molecular Formula C32H36ClNO8
CAS Registry Number 89778-27-8
SMILES CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O) O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain08.01.08.0040.000334%
Paresis17.01.04.008---
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.001---
Rash23.03.13.001---
Skin discolouration23.03.03.005---
Skin disorder23.03.03.007---
Thrombocytopenia01.08.01.002---
Thrombophlebitis24.01.02.001---
Thrombosis24.01.01.0060.000334%-
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Tremor17.01.06.002--
Uterine cancer16.12.05.001; 21.07.02.0030.000334%-
Uterine haemorrhage21.07.01.005; 24.07.03.004--
Uterine polyp16.04.02.002; 21.07.02.001---
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual field tests abnormal13.07.04.004---
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Deep vein thrombosis24.01.02.003---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Foetor hepaticus07.01.06.026; 09.01.05.006---
Musculoskeletal stiffness15.03.05.027---
Affect lability19.04.01.001---
Haemorrhage24.07.01.0020.000334%-
Metabolic disorder14.11.01.001---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages